Traitement systémique des métastases cérébrales de mélanome

Rhun Le Rhun; C. Mateus; L. Mortier; F. Dhermain; B. Guillot; J. J. Grob; C. Lebbe; M. Thomas; T. Jouary; M. T. Leccia; C. Robert

doi:10.1016/j.canrad.2014.11.010

Traitement systémique des métastases cérébrales de mélanome

Rhun Le Rhun, C. Mateus, L. Mortier, F. Dhermain, B. Guillot, J. J. Grob, C. Lebbe, M. Thomas, T. Jouary, M. T. Leccia, C. Robert

Résultats de recherche: Contribution à un journal › Brève enquête › Revue par des pairs

3 Citations (Scopus)

Résumé

Melanomas have a high rate of brain metastases. Both the functional prognosis and the overall survival are poor in these patients. Until now, surgery and radiotherapy represented the two main modalities of treatment. Nevertheless, due to the improvement in the management of the extracerebral melanoma, the systemic treatment may be an option in patients with brain metastases. Immunotherapy with anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) -ipilimumab- or BRAF (serine/threonine-protein kinase B-raf) inhibitors -vemurafenib, dabrafenib- has shown efficacy in the management of brain metastases in a- or pauci-symptomatic patients. Studies are ongoing with anti-PD1 (programmed cell death 1) and combinations of targeted therapies associating anti-RAF (raf proto-oncogene, serine/threonine kinase) and anti-MEK (mitogen-activated protein kinase kinase).

Titre traduit de la contribution	Systemic treatment of melanoma brain metastases
langue originale	Français
Pages (de - à)	48-54
Nombre de pages	7
journal	Cancer/Radiotherapie
Volume	19
Numéro de publication	1
Les DOIs	https://doi.org/10.1016/j.canrad.2014.11.010
état	Publié - 1 févr. 2015

mots-clés

BRAF inhibitors
Brain metastases
Ipilimumab
Melanoma

Accès au document

10.1016/j.canrad.2014.11.010

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{9310ef414779440dbd03937e92627d8d,

title = "Traitement syst{\'e}mique des m{\'e}tastases c{\'e}r{\'e}brales de m{\'e}lanome",

abstract = "Melanomas have a high rate of brain metastases. Both the functional prognosis and the overall survival are poor in these patients. Until now, surgery and radiotherapy represented the two main modalities of treatment. Nevertheless, due to the improvement in the management of the extracerebral melanoma, the systemic treatment may be an option in patients with brain metastases. Immunotherapy with anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) -ipilimumab- or BRAF (serine/threonine-protein kinase B-raf) inhibitors -vemurafenib, dabrafenib- has shown efficacy in the management of brain metastases in a- or pauci-symptomatic patients. Studies are ongoing with anti-PD1 (programmed cell death 1) and combinations of targeted therapies associating anti-RAF (raf proto-oncogene, serine/threonine kinase) and anti-MEK (mitogen-activated protein kinase kinase).",

keywords = "BRAF inhibitors, Brain metastases, Ipilimumab, Melanoma",

author = "{Le Rhun}, Rhun and C. Mateus and L. Mortier and F. Dhermain and B. Guillot and Grob, {J. J.} and C. Lebbe and M. Thomas and T. Jouary and Leccia, {M. T.} and C. Robert",

note = "Publisher Copyright: {\textcopyright} 2015 Soci{\'e}t{\'e} fran{\c c}aise de radioth{\'e}rapie oncologique (SFRO).",

year = "2015",

month = feb,

day = "1",

doi = "10.1016/j.canrad.2014.11.010",

language = "Fran{\c c}ais",

volume = "19",

pages = "48--54",

journal = "Cancer/Radiotherapie",

issn = "1278-3218",

number = "1",

}

TY - JOUR

T1 - Traitement systémique des métastases cérébrales de mélanome

AU - Le Rhun, Rhun

AU - Mateus, C.

AU - Mortier, L.

AU - Dhermain, F.

AU - Guillot, B.

AU - Grob, J. J.

AU - Lebbe, C.

AU - Thomas, M.

AU - Jouary, T.

AU - Leccia, M. T.

AU - Robert, C.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Melanomas have a high rate of brain metastases. Both the functional prognosis and the overall survival are poor in these patients. Until now, surgery and radiotherapy represented the two main modalities of treatment. Nevertheless, due to the improvement in the management of the extracerebral melanoma, the systemic treatment may be an option in patients with brain metastases. Immunotherapy with anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) -ipilimumab- or BRAF (serine/threonine-protein kinase B-raf) inhibitors -vemurafenib, dabrafenib- has shown efficacy in the management of brain metastases in a- or pauci-symptomatic patients. Studies are ongoing with anti-PD1 (programmed cell death 1) and combinations of targeted therapies associating anti-RAF (raf proto-oncogene, serine/threonine kinase) and anti-MEK (mitogen-activated protein kinase kinase).

AB - Melanomas have a high rate of brain metastases. Both the functional prognosis and the overall survival are poor in these patients. Until now, surgery and radiotherapy represented the two main modalities of treatment. Nevertheless, due to the improvement in the management of the extracerebral melanoma, the systemic treatment may be an option in patients with brain metastases. Immunotherapy with anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) -ipilimumab- or BRAF (serine/threonine-protein kinase B-raf) inhibitors -vemurafenib, dabrafenib- has shown efficacy in the management of brain metastases in a- or pauci-symptomatic patients. Studies are ongoing with anti-PD1 (programmed cell death 1) and combinations of targeted therapies associating anti-RAF (raf proto-oncogene, serine/threonine kinase) and anti-MEK (mitogen-activated protein kinase kinase).

KW - BRAF inhibitors

KW - Brain metastases

KW - Ipilimumab

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=84923366999&partnerID=8YFLogxK

U2 - 10.1016/j.canrad.2014.11.010

DO - 10.1016/j.canrad.2014.11.010

M3 - Brève enquête

C2 - 25656856

AN - SCOPUS:84923366999

SN - 1278-3218

VL - 19

SP - 48

EP - 54

JO - Cancer/Radiotherapie

JF - Cancer/Radiotherapie

IS - 1

ER -